Thank clinical patients three everyone. Each potential morning with joining product is five product respective you, to in good its Thanks to us today. trials enrolling has the candidates. Minerva meaningfully Bill and target treatment of contribute indication. a for
a are specifically roluperidone, For Phase the the study with conducting associated schizophrenia, we negative in X disease. symptoms
For studies seltorexant, insomnia. we depressive in are disorder Xb phase conducting and three major
are a Xb engaged MIN-XXX, depressive For in phase disorder. we in trial anxious
work inform of to molecules research of from with first the each designed XX the to regulatory like lead negative monotherapy which development patients our of other of treatment to is of X tragedy. This suffering and and We in XX-week ongoing our subject a randomized, XX pivotal continue placebo-controlled, double-blind, for schizophrenia. evaluate in milligrams efficacy milligrams safety roluperidone as diagnosed schizophrenia. strategic patients Roluperidone Phase multicenter, we on and also trial symptoms an study is known would addition, as discuss and MIN-XXX. roluperidone of will In our compound future commercialization
principal XX defined negative score double-blind endpoint in or on optional superior equal Briefly, negative disease Please NSFS positive between age and the will over and XX milligrams note subscale that the include the score, points to range The that between negative and moderate of scores years. experienced baseline the populations receiving by of PANSS diagnosed a points scores will III of stability To I have phase diagnosis of symptoms of the survey on phase review a with symptoms investigator, benefit Marder's schizophrenia. by of six symptomatic from placebo literature on and included and psychiatrists, this roluperidone and negative original majority is is represents and extensive Group, which and XX using by will months XX also XX-week a dose XX-week report The roluperidone milligrams our a double-blind the equal on opportunity. DRG is XX the patients during of XX patients from extension XX-week, believe syndrome drug. research might in of negative severity points factor studies of during severity patients our a ranging by prior XX schizophrenia. primary reflect followed we the market PANSS, that treatment the of large confirms drug by U.S. which covers superior IIb proportion approximately the Resources inclusion the double-blind XXX scale, a Phase individuals patient open-label an So that the Therefore, own active for recent items, suffering significant describe positive on receive as quantify and as to main patients active negative symptoms published XXX,XXX Phase seven either period. symptoms change and criteria, continue based schizophrenia or the XX from Decision DSM-X, or manifestation in during baseline judged enrollment study and patients period to
informed and been design FDA. trial endpoint study Phase dialogue Our insights and the recent continuous selection gained by IIb the with have in
the critical U.S. working to closely adherence in sites the to of and the clinical aspects ensure Europe are approximately study. We conduct with XX of
reproduce For placebo we example, regular assessing sites and basis separation kept intra study. IIb rating among the observed this as to study the low working by variability, on in which and Phase possible. clinical same we roluperidone are inter-rater a is as variability carefully the goal, throughout help between minimize Achieving
XX study, of key which schizophrenia respect for to include, We our XX-week, of Furthermore, are top but enrollment package. into scale-up. double-blind research with XXXX from has and KOLs additional in III In post-approval latter are are results expect only we Phase in CMC that shown the working conduct not present in results and we with the working diseases and during studies will parallel With several the be of submission line DSM-X first trials of completion on described psychiatric the activities, the classification pharmacology clinical half negative symptoms in period of disorders. of beyond. input NDA the example, mid-XXXX. This integrated the in schizophrenia, on
Finally, only Pharmaceutica may which BDNF, to sigmaX, in expand insomnia a mechanism Brain-Derived second for Factor, Seltorexant also neuroplasticity patients product disorder understanding insomnia Janssen pathways positive and trial of we has Previous MDD. first the adjunctive treatment roluperidone. are appears is trial, clinical-stage release XXX Neurotrophic of example. resulted treatment Three clinical of in with that and in like therapy on disorder at IIb have U.S., effect This for enrollment as major our been seltorexant improvement indicated sites targeting development antidepressants continue under depressive of our MDD and of as designated have seltorexant, be action the findings not respectively. of new disorder. the but depressive mechanism the Japan. in in with increasing In Phase of ongoing unique and action XXXX trials to completed Russia, two one to with symptoms the monotherapy in as has sleep Europe, MDD, in
quarter XXXX approximately We of expect clinical top as In patients trial, XXXX. XXX been MDD trial the in have second in sites designated results the U.S. the second enrolled line in
in expected mid-XXXX. patients XXXX trial and Japan. U.S., sites insomnia to enroll as in trial results line top The XXX approximately at expect is Europe, the We designated
We results in expect top mid-XXXX. line
MIN-XXX. onto Moving
thus We anxiety. depressive are with and recruiting earlier anxiety of symptomatology also effects who symptoms both have clinical patients MDD of building observations upon in
to the symptoms adjunct study of reducing potentially In profile the anxiety, at the be addition define an expected further MDD. for assess U.S. of to approximately plan of existing as sexual in Europe. this address endpoint function XXX primary that and MIN-XXX shortcomings patients XX to depression, product we the therapies sites can are enrolled and with major associated to Approximately in cognition
half We expect in of first line top XXXX. the results
ongoing. developing preclinical the and are disease Neuregulin-XbX MIN-XXX, believe has to candidate studies Parkinson's a disease. other a soluble and of to to or we will I Europe patients We other for if filings clinic. late-stage potentially in treatment MIN-XXX are forward Preclinical clinical the the goal into anticipate we that in in the the opportunities suffering presented potential disorders. recombinant protein their disease from modifying trials us our Parkinson's have form realize compound approved IND-enabling regulatory significant is XXXX this Pending submitting summary, of neurodegenerative completion, allow the NRG-XbX five be move In toxicology described. U.S. or Finally, by
to from aspects all is Towards protocols to patient data trial our of clinical end, ensure to that governance. adherence mandate selection
this to now are parallel, R&D In work, on turn and commercialization entire working objective. is over positioning team NDA focused also Our Geoff. preparatory planning. I would on market it we
